A weight-loss compound that acts on two receptors involved in appetite and blood sugar regulation. Studied for weight reduction, improved blood glucose control, and improvements in heart and metabolic health markers. Known for a steadier appetite-suppression curve and fewer gastrointestinal side effects than earlier weight-loss compounds such as Semaglutide.
Tirzepatide is a dual GLP-1 and GIP receptor agonist. GLP-1 activity slows gastric emptying, reduces appetite, and increases insulin release in response to meals. GIP adds an additional insulinotropic signal and has been shown to reduce GLP-1-related nausea — which is why tirzepatide tends to be better tolerated than pure GLP-1 agonists. Together they produce complementary reductions in food intake and improved glucose metabolism.
Appetite declines progressively as the dose is established. Gastric emptying slows, extending satiety. Post-meal blood glucose spikes flatten out. Over months, visceral and subcutaneous fat both reduce. Most users note fewer gastrointestinal symptoms than with semaglutide at equivalent stages of titration.
Enhances insulin signalling and metabolic flexibility — synergistic with GIP/GLP-1 dual action
Supports cellular energy and mitochondrial repair during caloric deficit
Targets deep visceral fat via growth hormone release — complementary mechanism for body recomposition
Not medical advice. Not a substitute for medical care. Consult your licensed practitioner before beginning any protocol. Peptides are sold for research purposes only and are suitable for adults aged 18 years and over.